Home > Result Summaries: Compounds > ropinirole > Result Summary for 101468/044

Result Summary for 101468/044

Result Summary

Protocol ID:	101468/044
Clinical Study ID:	SKF 101468/044
Official Title:	A Double-Blind, Placebo Controlled, Parallel Group Study of Oral Doses of Ropinirole for Six Months Treatment of Adjunct Therapy in Parkinsonian Patients Not Optimally Controlled on L-Dopa (DCI)
Phase:	Phase 3
Study Indications or Diseases:	Parkinson Disease
Generic Name:	ropinirole
Trade/Product Name:	requip;requip
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Brunt, E. R.; Brooks, D. J.; Korczyn, A. D.; Montastruc, J. L., and Stocchi, F. (Department of Neurology, University Hospital, Groningen, The Netherlands.). A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. [eng]. Brunt, E R; Brooks, D J; Korczyn, A D; Montastruc, J-L, and Stocchi, F. J Neural Transm. 2002 Apr; 109(4):489-502; Lieberman A, Olanow CW, Sethi K et al. A multicentre trial of ropinirole as adjunct treatment for Parkinsons disease. Neurology 1998; 51: 10571062